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Background: Chronic pain is prevalent, costly, and clinically vexatious. Clinicians typically use a trial-and-error approach
to treatment selection. Repeated crossover trials in a single patient (n-of-1 trials) may provide greater therapeutic
precision. N-of-1 trials are the most direct way to estimate individual treatment effects and are useful in comparing the
effectiveness and toxicity of different analgesic regimens. The goal of the PREEMPT study is to test the ‘Trialist’ mobile
health smartphone app, which has been developed to make n-of-1 trials easier to accomplish, and to provide patients
and clinicians with tools for individualizing treatments for chronic pain.
Methods/design: A randomized controlled trial is being conducted to test the feasibility and effectiveness of the
Trialist app. A total of 244 participants will be randomized to either the Trialist app intervention group (122 patients) or
a usual care control group (122 patients). Patients assigned to the Trialist app will work with their clinicians to set up an
n-of-1 trial comparing two pain regimens, selected from a menu of flexible options. The Trialist app provides treatment
reminders and collects data entered daily by the patient on pain levels and treatment side effects. Upon completion of
the n-of-1 trial, patients review results with their clinicians and develop a long-term treatment plan. The primary study
outcome (comparing Trialist to usual care patients) is pain-related interference with daily functioning at 26 weeks.
Discussion: Trialist will allow patients and clinicians to conduct personalized n-of-1 trials. In prior studies, n-of-1 trials
have been shown to encourage greater patient involvement with care, which has in turn been associated with better
health outcomes. mHealth technology implemented using smartphones may offer an efficient means of facilitating
n-of-1 trials so that more patients can benefit from this approach.
Trial registration: ClinicalTrials.gov: NCT02116621, first registered 15 April 2014.
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Chronic pain is highly prevalent [1] costly [2], and clinic-
ally vexatious [3]. Twenty percent of primary care pa-
tients are estimated to have persistent pain [4]. Patients
experiencing persistent or chronic pain are more likely
to have an anxiety or depressive disorder; they also are
more likely to have limitations in physical functioning* Correspondence: rlkravitz@ucdavis.edu
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unless otherwise stated.than patients without pain [4,5]. Pain is estimated to
cost the United States (US) economy $560 to 630 billion
annually due to health care expenditures and lost prod-
uctivity [2]. Musculoskeletal pain is the most common
reason for work disability and work absence [6].
Drug therapy is a mainstay of chronic pain management
in primary care. Current drug treatment strategies for
chronic painful conditions convey a mix of benefits and
hazards. In usual practice, clinicians often begin with acet-
aminophen or a non-steroidal anti-inflammatory drug
(NSAID), prescribing opioids when pain is severe or unre-
sponsive [7,8]. When the analgesic response to the initialis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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care, dose titration, opioid rotation, or augmentation with
adjuvants such as anti-convulsants [8-10]. These ap-
proaches are usually employed in a non-systematic, trial-
and-error fashion [11], which can appear to work in the
short run but may lead to poor therapeutic decisions in
the long run. A treatment that appears effective over a
short period may only seem so because of random fluctu-
ation in the patient’s underlying condition, uncontrollable
external factors, placebo effect, or regression to the mean
[7,12].
N-of-1 trials are single-subject crossover experiments
[13] in which a patient completes repeated treatments
comparing two treatment regimens. Also called single-
patient trials [14], single-subject trials [15], single-case
experiments [16], and individual-patient trials [14], n-of-
1 trials switch patients back and forth between two
treatments several times. Clinicians can then identify the
more effective approach for an individual patient [12].
N-of-1 trials are appropriate for chronic, stable condi-
tions and for treatments that have a rapid onset [14] and
short half-life [15]. They are particularly suitable when
available therapies are thought to have substantial het-
erogeneity of treatment effects (HTE), implying signifi-
cant variation across patients as to which treatment
works best. When HTE is large, average effects may mis-
lead, calling for a more personalized approach [17].
N-of-1 trials are the most direct way to estimate indi-
vidual treatment effects [14]. However, n-of-1 trials
have not yet gained traction with clinicians, patients,
and the scientific community. A major barrier is the
perception that such trials demand too much time and
effort [18]. The use of mobile health (mHealth) tech-
nologies to enhance care access and delivery [19] is a
promising approach to reduce perceived barriers to n-
of-1 participation. Smartphones are increasingly used in
care innovation research [20] and provide an opportun-
ity to develop interventions at lower cost and with de-
creased provider burden [21] than was possible before
the integration of mobile technologies into daily life.
Smartphones have been used to improve pain and
health outcomes through the use of specialized soft-
ware applications (apps) for assessing symptoms, facili-
tating communication between patients and providers,
tracking outcomes [22], delivering information [23] and
tracking behaviors. In pain settings, apps have been de-
veloped to record diary entries [24-26] and allow thera-
pists to send tailored text messages to patients [26]. In
non-pain settings, smartphones have been used in ran-
domized controlled trials (RCTs) to track physical ac-
tivity [27], monitor weight loss [21], and improve
nutrition [28]. More than 125 million people in the US
own smartphones, 50 million people own tablets [29],
and smartphones account for more than 50% of mobilephone sales. Android (for example, Google Nexus series
(Google, Mountain View, CA, USA), Samsung Galaxy
series (Samsung, San Jose, CA, USA)) and iOS (for ex-
ample, iPhone, iPad, iPod Touch (Apple Inc., Cupertino,
CA, USA)) devices account for over 90% of the smart-
phone market [29].
N-of-1 trials have the potential to expand patient in-
volvement and promote more personalized, patient-
centered health care. From the population perspective, if
mHealth-based n-of-1 trials can help patients and clini-
cians achieve therapeutic success faster and with greater
confidence, patients may require fewer subsequent office
visits, tests, emergency room visits, and after-hours tele-
phone support, thus lessening the burden on health sys-
tems and saving money.
The goal of the PREEMPT (Personalized REsEarch for
Monitoring Pain Treatment) study is to make n-of-1 trials
easier to accomplish, to provide patients and clinicians
with tools for individualizing treatments for chronic pain,
and to evaluate this approach in terms of patient out-
comes. A smartphone app called the ‘Trialist’ has been de-
veloped in collaboration with Open mHealth, a non-profit
mobile health developer. The feasibility and efficacy of the
‘Trialist’ smartphone app is being assessed in a RCT to
compare the effects of participating in a mobile n-of-1
trial versus usual care on patient outcomes including
pain-related interference with daily functioning, pain in-
tensity, participatory decision-making, medication adher-
ence, and general health-related quality of life. Achieving
these aims will set the stage for broader uptake of
mHealth n-of-1 trials in chronic pain as well as other
chronic health conditions.
Methods/design
PREEMPT is a RCT with a planned total of 244 partici-
pants randomized to the Trialist app intervention or a
usual care control group.
Study setting
The study is located in Northern California with recruit-
ment occurring within the University of California, Davis
(UC Davis) Primary Care Network, UC Davis Family
Medicine Clinic, UC Davis General Internal Medicine
Clinic, and the Veterans Affairs Northern California
Health Care System (VANCHS). These networks are lo-
cated within the greater metropolitan areas of Sacra-
mento and Yolo counties.
Study hypothesis
The primary study hypothesis is that, compared to usual
care, patients randomized to the Trialist will experience
less pain interference (impairment of daily functioning
including work outside the home, housework, and social
activities) at 26 weeks follow-up. Secondary hypotheses
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Trialist will experience less pain interference, less pain
intensity, better general health-related quality of life, im-
proved participatory decision-making, greater satisfac-
tion with pain treatment, better adherence to prescribed
therapy, and a better patient experience with care, each
measured as longitudinal change from baseline up to 52-
weeks follow-up.Eligibility criteria
Study participants include patients as well as their regu-
lar treating clinicians. Clinicians are recruited first, and
must have completed residencies in internal medicine,
family medicine, or pain medicine or be practicing nurse
practitioners or physician assistants. Patients, recruited
from the practices of consenting clinicians, are required
to meet the following criteria: English speaking adults
between 18 and 75 years old who have experienced on-
going musculoskeletal pain for 6 weeks or longer; own
an eligible iOS or Android smartphone or tablet; have a
pain score of 4 or higher (on a 0 to 10 scale where 10 is
the ‘worst pain imaginable’) on at least 1 of 3 items from
the PEG pain scale [30,31]; and in the judgment of the
treating clinician, have pain potentially amenable to
treatment with acetaminophen, NSAIDs, low-dose opi-
oids, tramadol, a complementary/alternative treatment
such as massage or meditation, or a combination of
these treatments (since these treatments are among
those offered on the Trialist ‘menu’). Patients are ex-
cluded if they are pregnant or breastfeeding; have under-
gone surgery, radiation or chemotherapy treatment for
cancer in the past 5 years; or have other medical condi-
tions or behaviors, such as bipolar disorder or current
alcohol or prescription drug abuse, rendering them un-
suitable for the trial. (See Table 1 for a complete list of
patient inclusion and exclusion criteria.)Table 1 Patient inclusion and exclusion criteria
Inclusion criteria
Experienced musculoskeletal pain for 6 weeks or longer
Between 18 and 75 years old
Android or iOS smartphone or tablet with a data plan and/or connected
to a home WiFi network
A score of 4 or greater for at least one question of the PEG pain scale [31]
Based on clinician judgment the patient is amenable to treatment with
acetaminophen, non-steroidal anti-inflammatory drugs, short-acting opioids,
tramadol, a complementary/alternative treatment such as massage or
meditation, or a combination of these treatments
Ability to speak and read EnglishRecruitment
Clinicians are recruited via flyers, Emails, letters and pre-
sentations. Once clinicians indicate interest, informed
consent is obtained detailing their responsibilities and soli-
citing their consent to have their patients recruited into
the study. Clinicians receive a $100 gift card for each pa-
tient who is enrolled and guided through the study.
Two methods are used for patient recruitment. First,
clinicians can ask patients directly if they are interested
in the study. Clinicians provide interested patients with
a study flyer that provides research staff contact infor-
mation. Second, patients of enrolled clinicians who have
been seen within the past 2 to 12 months for a chronic
painful condition (as indicated by appropriate Inter-
national Statistical Classification of Diseases and Related
Health Problems (ICD-9) codes) are sent an informa-
tional letter informing them about the study and inviting
them to contact research staff if interested in learning
more. Both patient recruitment methods rely on pa-
tients initiating contact with PREEMPT study research
staff. (See Figure 1 for the participant flow diagram and
Additional file 1 for the ICD-9 codes.) For completing
the study, patients receive a gift card worth $50 (con-
trol patients) or $100 (intervention patients).Screening
Patients are screened for eligibility over the telephone.
Research staff explain the study and ask initial screening
questions to assess pain levels and determine that the
patient has an eligible device. At this time, permission is
obtained from the patient to contact his/her clinician for
medical history screening. If permission is granted, the
patient’s clinician is contacted via secure Email and/or
telephone to verify that the patient is an appropriate
candidate for the study. Eligible patients are then recon-
tacted by telephone or Email, notified of eligibility, andExclusion criteria
Currently pregnant or breastfeeding
Received surgery, radiation or chemotherapy treatment for cancer
in the past 5 years
Patient has a medical condition/s that would limit the patient life
expectancy to < 2 years or imperil patient safety
Dementia, bipolar disorder, schizophrenia, or active suicidality
Evidence of alcohol or prescription drug abuse, or have a history
of disruptive behavior
Failed five or more analgesic medications because of lack of
effectiveness or poor tolerance
Figure 1 Participant flow through recruitment process.
Barr et al. Trials  (2015) 16:67 Page 4 of 11asked the date and time of their next clinic appointment.
Once a patient is deemed eligible, a consent packet is
mailed or Emailed with the study consent form and
Health Insurance Portability and Accountability Act
(HIPAA) authorization form. Informed consent will be
obtained from all participants included in this study.
Randomization and allocation concealment
Patients are randomized to Trialist versus usual care.
Randomization is stratified by clinician; each clinician’s
patients are randomized in blocks of size 4 (90% of
blocks) or 6 (10% of blocks) in order to balance the
numbers of participants per clinician and to minimize
selection bias. Patients assigned to usual care will receive
the usual course of care as prescribed by their clinician.
The allocation sequence are generated by the study stat-
isticians (CS and JS) and provided to the study coordin-
ator (MM) in a format that allows for clinician block
size to be masked until the study is completed and for
patient randomization allocation to be masked until
completion of the enrollment procedures.
Enrollment interview
The enrollment interview is conducted by research
staff and occurs just prior to the patient’s outpatientappointment in the clinic waiting room. If the signed
consent form and HIPAA authorization form (allowing
the research team access to the patient’s medical re-
cords) have not been received prior to the enrollment
interview, these documents are obtained first for each
patient. Then the patient’s randomization assignment
to either the Trialist app or usual care is revealed, and
the patient completes a baseline questionnaire. At this
visit, all patients receive a pain self-management book-
let [32].
Trialist intervention
Patients assigned to the intervention arm undergo a
‘Treatment Planning Visit’ with their clinician during a
regularly scheduled appointment to design the patient’s
n-of-1 trial. Clinicians and patients use the desktop
interface of the Trialist together to select two treatment
regimens for comparison. The customized option allows
patients and clinicians to select from among acetamino-
phen; any NSAID (for example, ibuprofen, naproxen); an
opioid combination product containing codeine, hydro-
codone or oxycodone; tramadol; or complementary/al-
ternative treatments such as massage, meditation or
physical exercise. The participating provider’s clinical
judgment and discussion with the patient determines
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mens for comparison can be single agents (for example,
acetaminophen) or combinations (for example, acet-
aminophen plus tramadol). Thus, the design of n-of-1
trials may range from simple (for example, acetamino-
phen versus low-dose hydrocodone/acetaminophen) to
complex (low-dose acetaminophen/hydrocodone plus
music therapy versus naproxen plus tramadol). If a clin-
ician attempts to select combinations that are clinically
inappropriate (for example, selecting two products both
containing acetaminophen to be administered simultan-
eously), the Trialist will disallow that selection. The
desktop interface also provides links to current prescrib-
ing standards and recommendations for the available
drug treatment options. (See Additional file 2 for screen-
shots of the desktop interface.) Allowable n-of-1 trials
will last a total of 4 to 12 weeks depending on the trial
parameters selected. Trial parameters include the dur-
ation a patient is on each treatment before switching
treatments (7 or 14 days), and the number of treatment
pairs (cycles) they complete (2, 3, or 4). At least two cy-
cles (for example, ABAB, BABA, ABBA, or BAAB) are
required for a valid n-of-1 trial. (See Table 2 for exam-
ples of possible trial configurations.) The clinician and
patient jointly select a start date for the n-of-1 trial,
allowing for time to fill prescriptions. The n-of-1 trial
parameter bounds were selected to provide a comprom-
ise between greater precision (for example, increasing
number of cycles), and practicality (that is trial lengths
that maintain patient interest).
After an n-of-1 trial is set up, patients are provided login
credentials for the Trialist smartphone app. The app is
available free on Google Play and Apple’s App Store.
Research staff provide patients with information on how to
use the Trialist app, including a help guide and an online
video tutorial (available on the study website, http://www.
ucdmc.ucdavis.edu/chpr/preempt/). Research staff also
provide patients with ongoing technical support.
The Trialist app randomizes the treatment sequence
and notifies the patients of the treatment they are sched-







7 2 4 Aa Ba B
3 6 A B B
4 8 B A B
14 2 8 A B
3 12 A B
aA and B are the alternative treatment regimens.tracking levels of pain and side effects of treatment such
as fatigue and drowsiness, and provides daily reminders
to complete the questionnaires. Most patients receive an
8-item daily questionnaire and 1 weekly question on ad-
herence. Patients experiencing neuropathic pain can
choose to specifically track 3 neuropathic symptoms (for
a total of 11 daily items). Example daily questions in-
clude: ‘What number best describes your pain on aver-
age during the past 24 hours?’ on a 0 to 10 scale; ‘I felt
fatigued during the past 24 hours’ on a 5-point scale
from ‘not at all’ to ‘very much’; and ‘How often did you
feel drowsy or sleepy today?’ on a 6-point response scale
from ‘not at all’ to ‘very much’. The raw data are not in-
cluded in the patient’s medical record, and are not available
to other applications outside of the Trialist infrastructure.
Patients receive notifications on their device to change
treatments after 7 or 14 days and to complete daily and
weekly questionnaires, and they also receive motivational
messages keying off their progress in the trial. Patients can
also view a graph of their own data to date, which displays
scores from the questionnaires in chronological order (see
Figure 2). Adherence to the daily questionnaires is essential
to ensure successful completion of a patient’s n-of-1 trial.
To improve adherence, patients are contacted by telephone
and/or Email for: a) failure to start a trial by pressing the
‘start button’ in the Trialist app within 48 hours after a trial
is due to start or b) completing fewer than 4 daily ques-
tionnaires in any week of the trial. All adherence-related
support and contact with patients is recorded. See Figure 3
for screenshots of the Trialist app.
Upon completion of the n-of-1 trial, patients review
trial results with their clinician during a ‘Results Review
Session’. This visit occurs during a regularly scheduled
office appointment. Clinician and patients will be ad-
vised to schedule a primary care appointment within
4 weeks of completing an n-of-1 trial, allowing treatment
decisions to occur shortly after a trial is completed. Cli-
nicians access the patient’s n-of-1 trial results using the
Trialist desktop interface. The results are displayed in a
series of graphs and text output. Six graphs will be dis-
played including raw data outputs and graphs showinge Trialist
4 5 6 7 8 9 10 11 12
A
A A B
A A B B A
B A
B A A B
Figure 2 Screenshot of the Trialist app showing a graph of a
user’s responses to the daily questionnaire.
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Additional file 3 for the graphs available to a clinician
and patient at the Result Review Session.)
Patient measures
Patient measures are assessed at baseline, 13-, 26-, and
52 weeks through completion of an online or mailed
questionnaire, with method of delivery based upon patient
preference. Patient demographics, length of provider-
patient relationship, and smartphone usage are measured
at baseline. The domains measured at each time point in-
clude pain interference, pain intensity, self-reported adher-
ence, participatory decision-making, satisfaction with pain
treatment, trust in their clinician, and general health-
related quality of life (HRQL). Study patients receive up to
$50 (out of total incentive amount) for completing all the
questionnaires.Pain interference
Pain interference is assessed using the Patient Reported
Outcomes Measurement Information System (PROMIS)
adult Short Form v1.0 - Pain Interference 8a. The scale
includes 8 items answered on a 5-point response scale
(‘not at all’ to ‘very much’). Questions include: ‘How
much did pain interfere with your day-to-day activities?’
and ‘How much did pain interfere with your family life?’
Further information on the PROMIS scales and mea-
sures are available from www.nihpromis.org.
Pain intensity
Pain intensity is assessed using the PROMIS adult scale
v1.0 - Pain Intensity 3a. The scale includes 3 items on a
5-point response scale from ‘no pain’ to ‘very severe’.
Questions include: ‘In the past 7 days, how intense was
your pain at its worst?’ ‘In the past 7 days, how intense
was your average pain?’ and ‘What is your level of pain
right now?’
Self-reported adherence
Self-reported adherence to pain treatment is assessed
using the four-item Analgesic Adherence Scale devel-
oped to assess general medication adherence. The scale
was developed by Rosser et al. [33], who replicated the
work of McCracken et al. [34]. The scale comprises 4
items on a 5-point response scale (‘never’ to ‘always’).
Questions include: ‘How often do you take less medica-
tion (smaller doses) than prescribed?’ and ‘How often do
you miss a dose of medication?’.
Participatory decision-making
Four items drawn from the Consumer Assessment of
Healthcare Providers and Systems (CAHPS) Patient-
Centered Medical Home Survey assessing shared
decision-making are included. The scale includes 2 items
on a 4-point response scale (‘not at all’ to ‘a lot’), and 2
‘yes/no’ questions. Questions include: ‘In the last
12 months, did you and this provider talk about starting
or stopping a prescription medicine?’ and ‘When you
talked about starting or stopping a prescription medi-
cine, how much did this provider talk about the reasons
you might want to take a medicine?’ [35-37].
Pain treatment satisfaction
Satisfaction with pain treatment is assessed using 22 items
from the 61-item Pain Treatment Satisfaction Scale devel-
oped by Evans et al. [38]. Questions are asked on five-
point response scales and assess how much information a
patient would like to receive about their treatment, ques-
tions about a patient’s medical care (for example, ‘The
medical staff is willing to provide me with the pain medi-
cation that I feel I need’), and questions about a patient’s
Figure 3 Screenshots of the Trialist app showing a question from the daily questionnaire and the ‘Reminders’ screen.
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tion has a positive effect on my physical health’).
Patient-provider relationship
The patient-provider relationship is assessed using an
adapted version of the 11-item Trust in Physician Scale
developed by Thom et al. [39], where the term ‘provider’
is substituted for ‘doctor’. This allows the scale to be
used with nurse practitioners and physician assistants.
Questions are asked on a five-point response scale (‘to-
tally agree’ to ‘totally disagree’). Questions include: ‘I
trust my provider to put my medical needs above all
other considerations when treating my medical prob-
lems’ and ‘My provider is well qualified to manage (diag-
nose and treat or make appropriate referral) medical
problems like mine’.
General health-related quality of life (HRQL)
General HRQL is assessed using the 10-item PROMIS
global health scale v.1.0/1.1 [40]. The scale includes 9
items on a 5-point response scale and one item on a 0
to 10 numerical scale. Questions include: ‘In general,
how would you rate your physical health?’ and ‘How
would you rate your pain on average?’
Demographics
Demographic data will be gathered on age, gender, mari-
tal status, race, ethnicity, employment and educational
attainment. All demographic questions will be asked atbaseline; marital status will be also re-assessed at 26 weeks,
and employment status will be assessed at 13-, 26- and
52 weeks.
Smartphone usage
Smartphone usage will be assessed at baseline using a
six-item scale to determine familiarity and frequency
with smartphones and apps. Questions include: ‘How
long have you been using a smartphone?’ (less than
6 months; between 6 months and 1 year; more than
1 year), and ‘Do you have any health-related Apps on
your smartphone?’ (yes, no). Two questions are adapted
from the smartphone and medical related app use
questionnaire created by Payne [41].
Patient and clinician relationship length
Patient and clinician relationship length is assessed using
2 questions (items 3 and 4) from the 34-item CAHPS
12-month Clinician & Group Visit Survey. The ques-
tions assess how long the patient has been going to the
provider and the number of visits to the provider in the
last 12 months [42].
Measures for intervention patients only
Patient trial expectations and experiences
Participants randomized to the Trialist app intervention
group complete a Patient Expectations and Patient Expe-
riences Questionnaire administered at the Treatment
Planning Visit (pre-trial) and at the Result Review Visit
Barr et al. Trials  (2015) 16:67 Page 8 of 11(post-trial). The purpose of this questionnaire is to
evaluate intervention patient expectations and experi-
ences with treatment and the extent to which patient ex-
pectations were met. Questions are asked on a five-point
response scale.Trialist acceptability and satisfaction questionnaire
Intervention patients also complete the Trialist Accept-
ability and Satisfaction Questionnaire to provide feed-
back on the use of the Trialist app. The survey is sent to
participants after the n-of-1 trial is completed. Questions
contained in the survey are based upon adaptations of
the System Usability Scale [43], and the Program Ac-
ceptability and Satisfaction Survey [44]. Questions are
asked on five-point response scales (‘strongly disagree’ to
‘strongly agree’) and (‘not at all helpful’ to ‘extremely
helpful’). Questions include: ‘I thought the Trialist app
was easy to use’ , ‘I found the Trialist app very awkward
to use’, and ‘How satisfied were you with the reminders
you received to complete your questionnaires?’Clinician questionnaire
At baseline, clinicians answer a 19-item questionnaire
on their clinical specialty, clinical practice workload,
clinical trial experience, smartphone usage and demo-
graphic characteristics. Questions include: ‘What is the
average number of patients you see during a typical half-
day of practice?’ and ‘During your training, residency or
fellowship, how much clinical research experience did
you have?’Sample size
The sample size required for the proposed RCT is
based on the primary outcome: change from baseline to
26 weeks on the PROMIS pain interference scale. As-
suming that the minimally important difference is 0.4
SD difference (4 points) and that 10% of those who
enter the study will not complete an endpoint and will
therefore be assigned a change of 0, the full sample
(endpoint completers plus non-completers) would need
to show a 3.6-point difference in order for the com-
pleters to show a minimally important difference. As-
suming a common standard deviation of 10 points,
each group (Trialist app and usual care) would need to
include 122 patients (244 in total) in order to have 80%
power to detect a 3.6-point difference in means using a
2-group t-test with a 0.05 2-sided significance level.
Approximately 50 to 60 clinicians will be enrolled with
each clinician being asked to enroll four to eight patients
each. This reduces the burden required on any one
clinician by ensuring that the maximum number of
intervention patients for each clinician is two to four.Analytical plan
The primary analysis will be intent-to-treat which uses
all participants as randomized. Outcomes will be ana-
lyzed both as changes from baseline to a single time
point and as longitudinal evolutions in time. Changes at
a single point (for example, from baseline to 26 weeks)
between the groups will be compared by a t-test for con-
tinuous outcomes and chi-square test for binary out-
comes. Longitudinal outcomes will use mixed models
with a fixed effect of treatment and a random effect of
time and a random time by treatment interaction using
the appropriate generalized linear model link function
and distribution (normal for continuous outcomes; bino-
mial for binary ones; Poisson for counts). Additional ex-
ploratory analyses will examine: potential interactions of
treatment with covariates such as age, gender, type of
intervention, dosage, time on treatment, physician and
clinic.
When no endpoint is available (for example, no pain
measurements available at the 6-month time interval to
calculate the outcome of change from baseline), we will
use different approaches. In one, we will assume that no
change has occurred and impute a change of zero. This
will permit simple conservative assessments of single
time point analyses. Longitudinal models can accommo-
date missing outcomes by ignoring them under the as-
sumption that data are missing at random. We will also
use multiple imputation to permit comprehensive ana-
lyses with missing covariates and interactions.
Analysis of N-of-1 trial results within the trialist (intervention
group only)
As noted earlier, patients assigned to the Trialist are
prompted to enter data on a daily basis. At the end of
each person’s n-of-1 trial, statistical analysis is performed
in order to compare results on the two treatments. Each
n-of-1 trial requires a separate analysis and the analysis
is automated to run in the background once each n-of-1
trial is completed. The analysis consists of running dif-
ferent Bayesian models that make different assumptions
about the nature of the data (for example, data with and
without correlation over time, with and without carry-
over across interventions, and so on). The results of
these models are automatically compared as to which
best fits the data, and the simplest model that accurately
fits the data is chosen. The goal of the model checking is
to assure that the model that can provide the most ac-
curate and precise treatment effect is chosen. Automated
model choice is checked manually by the study statisti-
cians for all initial n-of-1 trials and then periodically
thereafter to ensure that reasonable models are being se-
lected. Robust models are preferred. Patients and clini-
cians are provided with an estimate of the treatment
difference, represented as the estimated percentage that
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its uncertainty (for example, 95% Bayesian confidence
interval) as well as the probability that each treatment is
the best for each outcome. Results are portrayed numer-
ically and graphically (see Additional file 3.) Interpret-
ation of results is left to the patient and clinician, but
clinicians will have access to instructional materials on
how to interpret the graphs generated by Trialist.
Data management and monitoring
Outcome assessments will be collected via Research Elec-
tronic Data Capture (RedCap) survey or pen-and-paper.
Data will be entered into RedCap databases [45]. All data
that requires manual entry (for example, from a pen-and-
paper surveys) will be entered by trained staff and undergo
data quality and accuracy checks. Any data patients enter
in the Trialist app is encrypted and uploaded to a secure
server using Transport Layer Security (TLS)/Secure
Sockets Layer (SSL) protocols [46,47]. A Safety Monitor-
ing Committee (SMC) has been established. The SMC is
an independent committee comprised of researchers and
clinicians who are (with one exception) not involved in
the study. SMC meetings are scheduled monthly, subject
to cancellation at the discretion of the SMC chair pro-
vided there are no adverse events, no unanticipated prob-
lems, and no other issues for discussion. Unanticipated
and adverse events will be reported to the SMC and to
the institutional review board in accordance with Univer-
sity of California, Davis and Veterans Affairs Northern
California Health Care System (VANCHS) procedures.
The SMC will report adverse events considered related to
the study directly to the National Institute of Nursing Re-
search (NINR) program official.
Ethics approval
Ethical approval was obtained from Institutional Review
Boards at the University of California, Davis (496804)
and the VANCHS (13-12-00717).
Discussion
The Trialist app allows chronic pain patients and their
clinicians to jointly set up and conduct personalized n-
of-1 trials. Patients with chronic pain are at risk for both
over-treatment and under-treatment. Thus the need for
new approaches to chronic pain management is urgent,
not least because of accumulating evidence that trad-
itional approaches such as trial-and-error are often inef-
fective [11], prescription opioid overdoses are increasing,
and prescription opioid abuse is a pressing clinical and
economic problem [48].
For patients who are uncertain about which of two
therapies to choose, or who have concerns about the
relative benefits or about the side effects of various treat-
ment options, or who have been on a treatment for along time and simply do not know whether that treatment
is working, n-of-1 trials can support more confident
decision-making. N-of-1 trials encourage greater patient
involvement with care, which has been associated with
better health outcomes [49]. One reason nurses, physi-
cians, and other practitioners ignore clinical evidence
is that they question its relevance. N-of-1 data collected
from their own patients or combined with similar data
from other practices may have greater personal sali-
ence and more direct applicability to clinical care de-
cisions [50].
N-of-1 trials have not gained traction in the research
community, and one issue has been the difficulty of
bringing n-of-1 trials to scale. The integration of smart-
phones and mHealth technology offers a possible solu-
tion, facilitating patient participation in n-of-1 trials and
in turn, realizing benefit from increased therapeutic preci-
sion. With mHealth n-of-1 trials, clinical practice incorpo-
rates elements of research by bringing rigorous research
design, outcomes assessment, and statistical analysis to
the clinic. A successful demonstration of mHealth n-of-1
trials could pave the way for broader use of n-of-1 trials in
chronic pain management and other chronic conditions.
Trial status
At the time of manuscript submission 43 clinicians and
64 patients have been enrolled, and 23 patients have
been randomized.
Additional files
Additional file 1: ICD-9 Codes for chronic pain related diagnoses.
Additional file 2: Trialist desktop interface.
Additional file 3: Trialist graphs available at the Result Review
Session.
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